American Journal of Kidney Diseases
Volume 40, Issue 1 , Pages 104-109, July 2002

Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin☆☆

Kidney Center and Central Laboratory, Tsuchiura Kyodo General Hospital, Ibaraki, Japan

Received 24 September 2001; received in revised form 22 March 2002; accepted 22 March 2002.

Abstract 

Recombinant human erythropoietin (rHuEPO) is used to correct anemia in the majority of hemodialysis patients, but a few patients can maintain greater hematocrits without the use of rHuEPO. We aim to investigate which factors stimulate erythropoiesis, other than rHuEPO, in hemodialysis patients. One hundred fifty-eight patients undergoing regular hemodialysis treatment participated in a cross-sectional study. To keep the target hematocrit of 30%, 133 patients (84%) were administered rHuEPO, but 25 patients (16%) did not need rHuEPO. Mean hematocrits were 33.4% ± 4.6% in patients who did not need rHuEPO and 30.9% ± 4.0% in those administered rHuEPO. In the analysis of factors contributing to the lack of requirement of rHuEPO with multivariate logistic regression analysis, years on dialysis therapy and body mass index (BMI) were determined to be independent factors with odds ratios of 1.12 (95% confidence interval [CI], 1.02 to 1.23; P = 0.02) and 1.36 (95% CI, 1.13 to 1.63; P = 0.001), respectively. Neither serum erythropoietin level, albumin concentration, nor normalized protein catabolic rate contributed to the lack of requirement of rHuEPO. BMI correlated closely with log serum leptin level (r = 0.55; P < 0.0001), and log serum leptin level correlated inversely with rHuEPO dose (r = −0.18; P = 0.03). These results indicate that 16% of hemodialysis patients could maintain greater hematocrits without the administration of rHuEPO, and independently contributing factors were greater BMI and more years on hemodialysis therapy. Regarding nutritional parameters, a relatively greater BMI, possibly through effects of greater leptin levels, may stimulate erythropoiesis in uremic patients even in the absence of sufficient erythropoietin production. © 2002 by the National Kidney Foundation, Inc.

Keywords:  Renal anemia, recombinant human erythropoietin (rHuEPO), body mass index (BMI), leptin, hemodialysis (HD)

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by a grant from the Society for Research of Renal Anemia.

☆☆ Address reprint requests to Atsushi Takeda, MD, Kidney Center, Tsuchiura Kyodo General Hospital, 11-7, Manabe shinmachi, Tsuchiura-shi, Ibaraki-ken, 300-0053, Japan. E-mail: takedas@d5.dion.ne.jp

 0272-6386/02/4001-0013$35.00/0

PII: S0272-6386(02)00013-6

doi:10.1053/ajkd.2002.33918

American Journal of Kidney Diseases
Volume 40, Issue 1 , Pages 104-109, July 2002